Invest in Protagonist Therapeutics Inc: A Stock Worth Looking At!
January 30, 2023
Trending News ☀️
Protagonist Therapeutics ($NASDAQ:PTGX) Inc. is a biopharmaceutical company that focuses on developing orally administered peptide-based drugs to treat rare and severe diseases. This makes it an ideal stock to consider investing in. Protagonist Therapeutics Inc.’s core strength lies in its ability to develop peptide-based drugs that are orally administered. The company is actively researching and developing treatments for rare diseases such as hereditary angioedema and hemophilia A. It is also working on treatments for gastrointestinal disorders, such as ulcerative colitis and Crohn’s disease, as well as other autoimmune diseases. The company has several drugs in its pipeline, some of which have already been approved by the US Food and Drug Administration (FDA). The drug has completed phase 1 clinical trials, and the company is currently conducting phase 2 clinical trials for the treatment of HAE.
In addition to developing its own drugs, Protagonist Therapeutics Inc. also engages in strategic collaborations with other pharmaceutical companies to develop and market its drugs. Overall, Protagonist Therapeutics Inc. is an excellent stock to consider investing in. It has a strong financial position and a promising pipeline of treatments for rare and severe diseases. Moreover, the company is actively engaged in strategic collaborations with other pharmaceutical companies, which further strengthens its position. With its current price, Protagonist Therapeutics Inc. is an ideal stock to consider.
Share Price
Investing in Protagonist Therapeutics Inc. (PRTA) is worth considering. On Thursday, PRTA stock opened at 13.2 and closed at 13.2, with a 0.2% increase from the prior closing price of 13.2. This modest gain shows that PRTA is a stable investment and could be a great addition to any portfolio. The company is focused on developing and commercializing peptide-based therapies for patients suffering from serious diseases such as cancer, inflammatory conditions and infectious diseases. PRTA has been successful in advancing their technologies and has developed various drug candidates with the potential to treat various diseases.
In addition, PRTA is exploring new opportunities to expand its pipeline and is actively seeking out partnerships with other companies or organizations to discover and develop novel therapies. This portfolio provides the company with a strong competitive advantage and helps them maintain a strong market position. The company’s strong track record of success in developing peptide-based therapies and their robust intellectual property portfolio make it an attractive option for investors. With PRTA stock currently trading at 13.2, it is worth considering as an investment opportunity. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 35.2 | -130.11 | -369.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -103.44 | 115.4 | 20.46 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 282.17 | 38.56 | 4.95 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -4.0% | – | -373.8% |
| FCF Margin | ROE | ROA |
| -296.5% | -32.1% | -29.1% |
VI Analysis
The VI app is an invaluable tool for investors looking to analyze the fundamentals of PROTAGONIST THERAPEUTICS. This analysis reflects the company’s long-term potential, as well as its current financial health. The VI Star Chart gives PROTAGONIST THERAPEUTICS an intermediate health score of 5/10, taking into account its cashflows and debt. This suggests that the company might be able to pay off debt and fund future operations. Investors who are looking for high-growth opportunities with a higher risk-reward ratio may be interested in such a company. According to the VI app, PROTAGONIST THERAPEUTICS is strong in terms of assets and growth, but weak in terms of dividend and profitability. This suggests that the company is still in the process of establishing itself, but could be a good investment for those looking for high-growth companies with higher risks. As such, investors should consider PROTAGONIST THERAPEUTICS’ financial fundamentals before investing in the firm. More…
VI Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Protagonist Therapeutics Inc offers an attractive investment opportunity for investors. The company’s leading-edge drug discovery technology, combined with its well-established drug development capabilities, has created a portfolio of promising therapeutic candidates with the potential to treat a variety of serious medical conditions. Its market valuation is attractive and the company’s share price has been rising steadily in recent months. The company has a strong balance sheet, with low debt and healthy cash levels.
Additionally, its experienced management team and experienced board of directors provide a solid foundation for future success. Overall, Protagonist Therapeutics Inc offers an attractive opportunity for investors to gain exposure to a promising growth stock.
